CDCA3 and non-small cell lung carcinoma: While it is clear that numerous CK2 substrates function in TKI-resistant NSCLC, our findings suggest that CDCA3, as a CK2 substrate, also contributes to modulating the TKI response and indeed the response to CX-4945.